Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Glycomimetics’ SEC disclosures can feel like decoding complex carbohydrate chemistry—especially when each 8-K details a new clinical milestone or a Form 4 signals executive confidence in an upcoming sickle-cell trial. If you’ve searched “Glycomimetics SEC filings explained simply,” you’re not alone.
Stock Titan turns that complexity into clarity. Our AI scans every document the moment it hits EDGAR, then delivers plain-English takeaways—so you can grasp efficacy data, financing terms, or partner updates in minutes, not hours. Whether you need the latest “Glycomimetics quarterly earnings report 10-Q filing” or want real-time alerts for “Glycomimetics Form 4 insider transactions real-time,” all the information is gathered and summarized in one place.
Use the platform to:
- Track “Glycomimetics insider trading Form 4 transactions” and spot buying or selling before material events.
- Read a “Glycomimetics annual report 10-K simplified” that highlights R&D spend, cash runway, and pipeline timelines.
- Dig into a “Glycomimetics proxy statement executive compensation” without wading through legalese.
- Stay informed with “Glycomimetics 8-K material events explained,” from trial setbacks to partnership announcements.
- Access concise “Glycomimetics earnings report filing analysis” that connects financials to ongoing studies.
Why it matters: Understanding Glycomimetics’ work on glycomimetic drugs for cancer and sickle cell hinges on knowing when trial phases advance, how much runway cash remains, and what “Glycomimetics executive stock transactions Form 4” reveal about management sentiment. With AI-powered summaries, real-time updates, and historical archives, “understanding Glycomimetics SEC documents with AI” is finally straightforward.
CRESCENT BIOPHARMA, INC. Schedule 13G/A discloses that multiple Biotechnology Value Fund-related entities and Mark N. Lampert report shared beneficial ownership of the issuer's ordinary shares as of June 30, 2025. Individual holdings reported include Biotechnology Value Fund, L.P. (BVF) with 707,116 shares (approximately 5.1% of 13,892,562 outstanding shares), Biotechnology Value Fund II, L.P. (BVF2) with 593,740 shares (approximately 4.3%), and Biotechnology Value Trading Fund OS LP with 62,383 shares (about 0.4%). Aggregated positions held or attributable through affiliated vehicles total 1,387,863 shares, representing approximately 9.99% of the class. The filing also states that Pre-Funded Warrants exercisable for an aggregate of 597,928 shares are held by the reporting persons but could not be exercised as of June 30, 2025 due to a 9.99% exercise blocker.
Logos Global Management and related entities report ownership stakes in Crescent Biopharma, Inc. The filing shows Logos Global Management LP and Logos Global Management GP LLC each have beneficial ownership of 575,000 ordinary shares, representing 4.1% of the class. Logos Global Master Fund LP and Logos GP LLC each report 100,000 shares (0.7%). The percentage figures are calculated using 13,829,562 ordinary shares outstanding as reported by the issuer for the quarter ended June 30, 2025.
The reported positions are held with shared voting and shared dispositive power; no reporting person claims sole voting or sole dispositive power. The filers state they are investment adviser/related entities and expressly disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. The filing includes certifications that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
